Merck's Idvynso Wins FDA Approval as First Non-INSTI, Tenofovir-Free HIV Regimen After Years of Safety-Driven Redesign
The FDA cleared doravirine/islatravir on April 21, completing a development program that was halted in 2021 over lymphocyte counts and restarted at a lower dose.
5 min read4 sources